Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness Wire • 11/24/20
Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceBusiness Wire • 11/09/20
Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare ConferenceBusiness Wire • 11/02/20
Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet SyndromeBusiness Wire • 10/07/20
Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse ModelBusiness Wire • 08/26/20
Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein ExpressionBusiness Wire • 07/09/20
Stoke Therapeutics, Inc. (STOK) Shares March Higher, Can It Continue?Zacks Investment Research • 12/19/19